Table 2.

Ovulation results and MI plasma concentration in patients undergoing the first and the second phase of the study

	MI plasma levels		Ovulation
	T0 μmol/l	T3 μmol/l	T3 (n)
First phase: treatment with MI alone for 3 months in all patients (no. = 37)	–	38 ± 2.9	23/37
Second phase: treatment with MI + α-LA for 3 (further) months in MI-resistant women (no. = 14)	17 ± 3.5a	35 ± 3.8b	12/14

Values are expressed as mean ± SD. T0 baseline; T3 end of treatment (three months)

^athis value was found in MI-resistant subjects in the first phase after MI treatment (T3) and represents the baseline value of the second phase

^bMI plasma levels in MI-resistant women at T3 were found to be significantly (p <  0.001) higher than at T0